Tumor material, ascites (if possible) and blood samples for immune monitoring will be collected from patients with primary and recurrent EOC undergoing surgery, chemotherapy and/or immunotherapy.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with (suspicion of) primary or recurrent EOC with an indication for surgery, chemotherapy and/or immunotherapy.
Age ≥18 years.
WHO performance status 0-2.
Accessible for treatment and follow-up.
Written informed consent.
You may not be if
Other active malignancy in past 5 years prior to entry into the study, except for treated non-melanoma skin cancer.
Any known severe infection like HIV, hepatitis A, B and C.
Receiving immune suppressive treatment.
Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.
Clareo Health | Determining Prognostic Immune Markers in Patients With Ovarian Cancer
